Matrix Biosciences
First biotech company spun out by VitaDAO, developing small molecule therapies that modulate hyaluronidases for cancer treatment and extending human healthspan and lifespan.
Notes
Matrix Biosciences is a pioneering biotechnology company and the first spinout from VitaDAO, the decentralized autonomous organization (DAO) focused on funding longevity research. Launched in October 2023 in collaboration with Dr. Vera Gorbunova from the University of Rochester's Aging Research Center, the company focuses on developing treatments for cancer and aging-related disorders.
The company's approach centers on developing small molecules that modulate hyaluronidases, enzymes involved in breaking down hyaluronic acid, with potential applications in cancer treatment and extending human healthspan and lifespan.
Team
- Dr. Vera Gorbunova - Scientific Co-Founder (University of Rochester)
- LinkedIn: linkedin.com/in/vera-gorbunova
Additional Research Findings
- First company spun out by VitaDAO (October 2023)
- Initial funding: $300,000 from VitaDAO
- Collaboration with University of Rochester Aging Research Center
- Focus on hyaluronidase modulation
- Cancer treatment applications
- Longevity and healthspan extension research
- Part of the growing decentralized science (DeSci) movement
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| VitaDAO | Decentralized (Global) | dao | seed | 7 |